openPR Logo
Press release

Emtricitabine and Tenofovir Market Growing Rapidly by 2031 - Gilead Sciences, Cipla & Mylan Pharmaceuticals.

09-05-2024 07:50 AM CET | Health & Medicine

Press release from: DataM Intelligence 4market Research LLP

Emtricitabine and Tenofovir Market || 2024-2031

Emtricitabine and Tenofovir Market || 2024-2031

The Emtricitabine/Tenofovir market is projected to grow at a compound annual growth rate (CAGR) of 5% during the forecast period from 2024 to 2031.

Emtricitabine/Tenofovir, marketed under the brand name Truvada, is a fixed-dose combination antiretroviral medication used for the treatment and prevention of HIV/AIDS. This combination consists of two antiretroviral drugs: Emtricitabine, a nucleoside reverse transcriptase inhibitor (NRTI), and Tenofovir disoproxil, a nucleotide reverse transcriptase inhibitor (NtRTI). Together, these medications work by inhibiting the enzyme reverse transcriptase, which is essential for viral replication in the body.

While Truvada is highly effective in managing HIV infection, it must be used in combination with other antiretroviral medications to fully suppress the virus. In addition to its role in treatment, Truvada is also widely used as a pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection in high-risk individuals, making it a cornerstone of HIV prevention strategies worldwide.

Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/emtricitabine-and-tenofovir-market

Market Trends:

An increase in the number of HIV/AIDS patients will drive the market.

Human immunodeficiency virus (HIV) targets the immune system, weakening the body's defense against various infections and certain cancers that a healthy immune system would typically fend off. The combination of Emtricitabine and Tenofovir (marketed as Descovy and Truvada) is used alongside other medications to treat HIV in adults and children weighing at least 37 pounds (17 kg). Additionally, Truvada is prescribed in combination with safer sex practices, like Safety use, to reduce the risk of HIV infection in high-risk adults and teenagers weighing at least 77 pounds (35 kg). Both Emtricitabine and Tenofovir belong to the class of nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), which slow the spread of HIV in the body.

HIV remains a significant global public health issue, having claimed approximately 34.7 million lives to date. The market growth for Emtricitabine/Tenofovir is expected to be driven by increasing drug approvals.
The range of available antiretroviral (ARV) drugs has expanded, with approvals of novel ARVs featuring new mechanisms of action and combination tablets of existing medications, such as Emtricitabine/Tenofovir.

Market Segmentation:

By Type: Outsourcing of API, Self-production API.

By Application: Hospitals, Clinics, Others.

Get Customization in the report as per your requierments: https://datamintelligence.com/customize/emtricitabine-and-tenofovir-market

Major Key Players:

• Gilead Sciences
• Cipla
• Mylan Pharmaceuticals
• Emcure Pharmaceuticals
• Hetero Drugs
• Sun Pharmaceutical Industries
• Alkem Laboratories
• Hengrui Medicine
• SYSVAX
• Hisun Pharmaceutical

Product Portfolio:

Overview: Gilead Sciences, Inc., based in Foster City, California, is an American biopharmaceutical company specializing in the research and development of antiviral drugs for treating HIV, hepatitis B, hepatitis C, and influenza, including well-known medications like Harvoni and Sovaldi. The company is committed to creating innovative treatments for severe and life-threatening illnesses. Gilead's management strategy focuses on fostering a sustainable future, driven by a dedication to integrity and excellence.

Regional Analysis:

The global Emtricitabine and Tenofovir Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The Emtricitabine and Tenofovir Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications.

Related Reports:

Semen Analysis Market: https://datamintelligence.com/research-report/semen-analysis-market

Pediatric Ventilators Market: https://datamintelligence.com/research-report/pediatric-ventilators-market

Affiliate Marketing Request here: https://www.datamintelligence.com/affiliate-marketing

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Emtricitabine and Tenofovir Market Growing Rapidly by 2031 - Gilead Sciences, Cipla & Mylan Pharmaceuticals. here

News-ID: 3645973 • Views:

More Releases from DataM Intelligence 4market Research LLP

United States Intravenous Anticoagulants Market to Reach USD 20.1 Billion by 2032 | Top Companies are Pfizer, Inc, Sanofi, Fresenius Kabi AG
United States Intravenous Anticoagulants Market to Reach USD 20.1 Billion by 203 …
The Intravenous Anticoagulants Market is anticipated to reach at a high CAGR during the forecast period. The Intravenous Anticoagulants market focuses on medications administered through IV to prevent or treat blood clots. These anticoagulants, such as heparin and direct thrombin inhibitors, are essential in managing conditions like deep vein thrombosis, pulmonary embolism, and during surgeries to reduce clotting risks. The market is driven by the rising prevalence of cardiovascular diseases, advancements
United States Biorational Pesticides Market to Reach US$ 18.85 Billion by 2031, Driven by Sustainable Farming and Green Agriculture Initiatives | Top Companies are BASF SE, FMC Corporation, Corteva
United States Biorational Pesticides Market to Reach US$ 18.85 Billion by 2031, …
Global Biorational Pesticides Market reached US$ 6.12 billion in 2023 and is expected to reach US$ 18.85 billion by 2031, growing with a CAGR of 15.1% during the forecast period 2024-2031. Biorational Pesticides Market includes natural or minimally toxic pesticides derived from microbes, plant extracts, or biochemical agents. Growth is driven by sustainable agriculture, regulatory restrictions on chemical pesticides, and organic farming trends. Applications include pest control in fruits, vegetables, and
United States Orthopedic Software Market to Reach USD 530.31 Million by 2031, Growing at a CAGR of 5.1% | Expanding Applications in Surgical Planning and Practice Management
United States Orthopedic Software Market to Reach USD 530.31 Million by 2031, Gr …
The Orthopedic Software Market is valued at a significant CAGR during the forecast period (2024-2031). Orthopedic software is specialized technology used in healthcare to manage, diagnose, and treat musculoskeletal disorders and injuries. This software helps orthopedic surgeons with patient data management, preoperative planning, surgical navigation, and post-operative care. It provides tools for imaging, such as X-rays and MRIs, to assist in diagnosing bone fractures, joint issues, and other orthopedic conditions. The
United States Hydrotreating Catalysts Market to Reach USD 1.74 Billion by 2031, Growing at a CAGR of 4.0% | Top Companies are Albemarle Corporation, BASF SE, Haldor Topsoe A/S
United States Hydrotreating Catalysts Market to Reach USD 1.74 Billion by 2031, …
Global Hydrotreating Catalysts Market reached US$ 1,284.2 million in 2023 and is expected to reach US$ 1,735.5 million by 2031, growing with a CAGR of 4.0% during the forecast period 2024-2031. Hydrotreating Catalysts Market involves catalysts used in refining petroleum to remove sulfur, nitrogen, and impurities. Growth is driven by fuel quality regulations, refinery upgrades, and cleaner fuel demand. Catalysts improve efficiency, yield, and environmental compliance. Refineries and chemical plants are

All 5 Releases


More Releases for Emtricitabine

Emtricitabine and Tenofovir Industry Size Share Growth Trends Leading Players Fo …
Emtricitabine and Tenofovir Market is the focal point of DataM Intelligence's latest market research report, offering a comprehensive analysis of this dynamic sector. This in-depth study goes beyond a basic overview, exploring the intricate dynamics that shape the market. By examining regional trends, demand patterns, and potential breakthroughs, DataM Intelligence aims to empower businesses and stakeholders with valuable insights for navigating the evolving landscape. The insights from this report can
Emtricitabine and Tenofovir Market 2024 Projections, Trends and Forecast 2024 - …
"Emtricitabine and Tenofovir Market 2024," The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Emtricitabine and Tenofovir market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Emtricitabine and Tenofovir industry, providing stakeholders with a
Emtricitabine/Rilpivirine/Tenofovir Alafenamide Market Share and Growth Factors …
Major advancements and key strategies depicted here are of great help to make gainful decision making and generate huge profits. This Emtricitabine/Rilpivirine/Tenofovir Alafenamide market report further talks about some significant factors that fuel and hinder the market growth. It further focuses on variables, which contribute greatly in the expansion of market growth. Perspectives of the expert on closest image of the entire market are also covered in the research analysis
Global Emtricitabine/Rilpivirine/Tenofovir Alafenamide Market to 2025 | Hospital …
Market Research Hub (MRH) has actively included a new research study titled Global Emtricitabine/Rilpivirine/Tenofovir Alafenamide Market Insights, Forecast to 2025 to its wide online repository. The concerned market is discoursed based on a variety of market influential factors such as drivers, opportunities and restraints. This study tends to inform the readers about the current as well as future market scenarios extending up to the period until forecast period limit; 2025.
Emtricitabine/Rilpivirine/Tenofovir Alafenamide Market - Global Market Overview …
The global market for Emtricitabine/Rilpivirine/Tenofovir Alafenamide is the focus of analysis of a recently added market intelligence report. The report begins with a detailed overview of the market that includes its current competitive dynamics, market size, and prospects going forward. To do so, it makes use of historical and current data drawn from various sources. Request Free Sample Copy of Report @ https://www.researchmoz.us/enquiry.php?type=S&repid=2374395 The global Emtricitabine/Rilpivirine/Tenofovir Alafenamide market is valued at xx
Global Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Combination D …
Researchmoz added Most up-to-date research on "Global Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Combination Drug Market Insights, Forecast to 2025" to its huge collection of research reports. An insight on the important factors and trends influencing the market. The global Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Combination Drug market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of